Uday R Popat, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Uday R Popat, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04859946 · Itacitinib for the Prevention of Graft Versus Host DiseaseM.D. Anderson Cancer Center · active not recruiting · Hematologic and Lymphocytic Disorder · principal investigator
- Ph2NCT02861417 · Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center · active not recruiting · Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome · principal investigator
- Ph1NCT01300611 · TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTarix Pharmaceuticals · terminated · Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.